Based on our results, we hypothesized that the molecular design of affibody-based therapeutics targeting HER3 in terms of the relative position of functional domains and valency has an impact on tumor targeting, biodistribution properties, and internalization rates. This evidence concerns the gene ERBB3 and neoplasm.